Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

被引：0
|
作者：
Chen, Robert W. [1 ]
Gopal, Ajay K. [2 ]
Smith, Scott E. [3 ]
Ansell, Stephen M. [4 ]
Rosenblatt, Joseph D. [5 ]
Savage, Kerry J. [6 ]
Connors, Joseph M. [7 ]
Engert, Andreas [8 ]
Larsen, Emily K. [9 ]
Sievers, Eric L. [9 ]
Younes, Anas [10 ]
机构：
[1] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA 91010 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Med Ctr, Seattle, WA 98195 USA
[3] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[6] BC Canc Agcy Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada
[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada
[8] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[9] Seattle Genet Inc, Bothell, WA USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3689.3689
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3689
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
    Tien, Feng-Ming
    Tsai, Cheng-Hong
    Liu, Jia-Hau
    Lin, Chien-Ting
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (10) : 1466 - 1470
  • [22] Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Huebner, Dirk
    Fong, Abraham
    Younes, Anas
    BLOOD, 2016, 128 (12) : 1562 - 1566
  • [23] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Kambhampati, Swetha
    Mei, Matthew
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro H.
    Kwak, Larry W.
    Rosen, Steve T.
    Forman, Stephen J.
    Herrera, Alex F.
    BLOOD, 2022, 140 : 9418 - 9419
  • [24] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Bartlett, Nancy L.
    Ramchandren, Radhakrishnan
    Vose, Julie M.
    Moskowitz, Alison J.
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Kato, Kazunobu
    Fong, Abraham
    Advani, Ranjana H.
    BLOOD, 2016, 128 (22)
  • [25] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10):
  • [26] Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
    Gandolfi, Letizia
    Pellegrini, Cinzia
    Casadei, Beatrice
    Stefoni, Vittorio
    Broccoli, Alessandro
    Tonialini, Lorenzo
    Morigi, Alice
    Argnani, Lisa
    Zinzani, Pier Luigi
    ONCOLOGIST, 2016, 21 (12): : 1436 - 1441
  • [27] Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
    Picardi, M.
    Della Pepa, R.
    Giordano, C.
    Pugliese, N.
    Mortaruolo, C.
    Trastulli, F.
    Rascato, M. G.
    Cappuccio, I
    Raimondo, M.
    Memoli, M.
    Monteverde, M.
    Mascolo, M.
    Pane, F.
    BLOOD ADVANCES, 2019, 3 (09) : 1546 - 1552
  • [28] A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
    Cao, Zhi-Gang
    Zhou, Hong-Wei
    Peng, Chao-Jin
    Liu, Mo
    Du, Yu
    Yang, Qing-Ming
    CHINESE JOURNAL OF CANCER, 2013, 32 (09) : 520 - 523
  • [29] Combination of nivolumab with brentuximab vedotin in therapy of relapsed and refractory Hodgkin lymphoma
    Fedorova, L.
    Lepik, K.
    Mikhailova, N.
    Kondakova, E.
    Kotselyabina, P.
    Shmidt, D. I.
    Kozlov, A.
    Zalyalov, Y.
    Borzenkova, E.
    Baykov, V.
    Moiseev, I.
    Kulagin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S655 - S655
  • [30] EXPERIENCE WITH BRENTUXIMAB VEDOTIN IN RELAPSED/ REFRACTORY HODGKIN LYMPHOMA IN THE PROVINCE OF CADIZ
    Verdugo Cabeza De Vaca, Ma V.
    Cuellar Garcia, C.
    Romero Gonzalez, Ma dM
    Fernandez Valle, Ma dC
    Berruezo Salazar, Ma J.
    Paz Coll, A.
    Garzon Lopez, S.
    HAEMATOLOGICA, 2015, 100 : 174 - 174
12345